Jaguar Health Raises Cash via Secondary Offering, Licenses Mytesi to Future Pak for $16M
JAGX has more than doubled off its 52-week low of $2.35 on elevated volume (26× avg).
Summary
Jaguar Health filed a 424B5 on Sept. 3 for a secondary offering to raise cash, citing over $25M in current liabilities and ongoing liquidity pressure. The company also signed a U.S. license deal with Future Pak for Mytesi and Canalevia-CA1, receiving $16M upfront plus $2M contingent, while retaining manufacturing. Additionally, Jaguar is advancing crofelemer powder toward a mid-2027 NDA for rare pediatric intestinal disorders, and the FDA waived the PDUFA fee for Canalevia-CA1. These moves address the going concern warning from the Q2 10-Q, where cash was only $3.8M. The offering is dilutive but the license provides immediate non-dilutive capital.
At the time of this announcement, JAGX was trading at $7.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4M. The 52-week trading range was $2.35 to $1,280.95. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.